Telepatia

Who is behind Telepatia and who has funded it?

The entity is Telepatía S.A.S., with a Medellín, Colombia address in the homepage's structured data, while Dealroom calls the company Brazilian. Nicolas Abad is founder and CEO. LatamList gives 2025 as the founding year, which is unverified, and press mentions incubation at Stanford.

Dealroom reported a $9M seed in October 2025 led by A-Star. LatamList reported the $33M Series A on June 18, 2026, led by Andreessen Horowitz with Shyam Sankar, Simón Borrero and David Vélez, and ColombiaOne puts the total at $42M. Press says the company aims to reach half of Latin America's 1.9 million doctors by the end of 2027.

Customer figures differ by page. The homepage meta says more than 1,000 doctors and 5 million consultations, the Portuguese page says 571 "vidas protegidas", the Spanish page 3,425, and press cites 14 million patients and 25-plus institutions. Colsubsidio, Comfama, Fundación Santa Fe de Bogotá, Mater Dei and Prosalco appear as logos.

What are the four modules?

Per the vendor, IA Escriba transcribes the consultation and drafts the note. IA CDSS flags interactions, allergies, doses and contraindications with a source, and the clinician accepts or rejects each flag. Telepatia Intelligence searches evidence with citations and calculates clinical scales. IA Auditora audits all notes, where the vendor says human auditors reach about 3%. Institutions can set custom note formats, institutional guidelines, role views and custom modules, and an audit log is kept.

The vendor reports that 40 to 60% of recommendations are accepted and that 20-plus systems are connected, without a method for either figure. Other software connects through an integrations team.

What does the security page promise?

Per the vendor's Portuguese security page, Telepatia is aligned with HIPAA and the Brazilian LGPD. It states encryption in transit and at rest, a log of every access, audio deleted once the note is done, and no training on audio, notes or records. SOC 2, ISO 27001, a BAA and data residency are not stated. No FDA, ANVISA or COFEPRIS registration appears on its pages.

What does it cost once the launch period ends?

The institutions page (November 2026) lists Individual at USD 99 a month, struck through next to a launch price of USD 0 with no end date. Institutional plans are quoted by team size and integration, and teams under six doctors need no contract. Free sign-up is at scribe.telepatia.ai. A YouTube review, "Escribas Médicos Inteligentes, ¿valen la pena?", recommends the free scribe, though its date and independence are unknown.

The verdict

The launch price is zero and testing takes a sign-up. The price after launch has not been announced.